227 related articles for article (PubMed ID: 35987486)
1. Safety of Biologics for Atopic Diseases During Pregnancy.
Shakuntulla F; Chiarella SE
J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3149-3155. PubMed ID: 35987486
[TBL] [Abstract][Full Text] [Related]
2. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation.
L Ramos C; Namazy J
Immunol Allergy Clin North Am; 2023 Feb; 43(1):187-197. PubMed ID: 36411004
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
Jackson K; Bahna SL
Expert Rev Clin Immunol; 2020 Mar; 16(3):311-319. PubMed ID: 31994421
[No Abstract] [Full Text] [Related]
6. Biologics in allergic rhinitis.
Bayar Muluk N; Cingi C
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Nopsopon T; Lassiter G; Chen ML; Alexander GC; Keet C; Hong H; Akenroye A
J Allergy Clin Immunol; 2023 Mar; 151(3):747-755. PubMed ID: 36538979
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review.
Bernstein JA; Llanos JP; Hunter G; Martin N; Ambrose CS
Adv Ther; 2023 Nov; 40(11):4721-4740. PubMed ID: 37698716
[TBL] [Abstract][Full Text] [Related]
9. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
10. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.
Menzies-Gow A; Steenkamp J; Singh S; Erhardt W; Rowell J; Rane P; Martin N; Ackert JL; Quinton A
J Med Econ; 2022; 25(1):679-690. PubMed ID: 35570578
[TBL] [Abstract][Full Text] [Related]
11. Strategies for choosing a biologic for your patient with allergy or asthma.
Saco T; Ugalde IC; Cardet JC; Casale TB
Ann Allergy Asthma Immunol; 2021 Dec; 127(6):627-637. PubMed ID: 34642091
[TBL] [Abstract][Full Text] [Related]
12. Biological treatments in childhood asthma.
Nieto-García A; Nieto-Cid M; Mazón-Ramos Á
Curr Opin Allergy Clin Immunol; 2024 Jun; 24(3):114-121. PubMed ID: 38567842
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Biologics for Oral Corticosteroid-Dependent Asthma: A Systematic Review and Network Meta-Analysis.
Phinyo P; Krikeerati T; Vichara-Anont I; Thongngarm T
J Allergy Clin Immunol Pract; 2024 Feb; 12(2):409-420. PubMed ID: 37972921
[TBL] [Abstract][Full Text] [Related]
14. The evolving landscape of immunotherapy for the treatment of allergic conditions.
Pandya A; Adah E; Jones B; Chevalier R
Clin Transl Sci; 2023 Aug; 16(8):1294-1308. PubMed ID: 37170653
[TBL] [Abstract][Full Text] [Related]
15. Biologics for oral corticosteroid-dependent asthma.
Yılmaz İ
Allergy Asthma Proc; 2020 May; 41(3):151-157. PubMed ID: 32375958
[No Abstract] [Full Text] [Related]
16. Clinical characteristics of complete responders versus non-complete responders to omalizumab, benralizumab and mepolizumab in patients with severe asthma: a long-term retrospective analysis.
Basagaña M; Martínez-Rivera C; Padró C; Garcia-Olivé I; Martínez-Colls M; Navarro J; Pardo L; Cruz P; Cardona Peitx G; Carabias L; Roger A; Abad J; Rosell A
Ann Med; 2024 Dec; 56(1):2317356. PubMed ID: 38364218
[TBL] [Abstract][Full Text] [Related]
17. [Biologics for the treatment of severe asthma: Current status report 2023].
Paçacı Çetin G; Kepil Özdemir S; Can Bostan Ö; Öztop N; Çelebi Sözener Z; Karakaya G; Gelincik Akkor A; Yılmaz İ; Mungan D; Bavbek S
Tuberk Toraks; 2023 Jun; 71(2):176-187. PubMed ID: 37345400
[TBL] [Abstract][Full Text] [Related]
18. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
[TBL] [Abstract][Full Text] [Related]
19. Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis.
Chen ML; Nopsopon T; Akenroye A
J Allergy Clin Immunol Pract; 2023 May; 11(5):1475-1484.e20. PubMed ID: 36716995
[TBL] [Abstract][Full Text] [Related]
20. Biologics for Asthma and Allergic Skin Diseases in Children.
De Keyser HH; Chipps B; Dinakar C;
Pediatrics; 2021 Nov; 148(5):. PubMed ID: 34663682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
